StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Aerie Pharma (AERI) PT Raised to $70 at Aegis Capital Following Phase III Trial
May 25, 2017 8:24 AM
Aegis Capital raised its price target on Aerie Pharma (NASDAQ: AERI) to $70.00 (from $63.00) while maintaining a ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst PT Change
Next Articles
Aerie Pharma (AERI): Now A Consolidation Candidate - Cowen
May 25, 2017 8:01 AM
Aerie Pharma (AERI): Raising PT On Roclatan Data - Needham
May 25, 2017 6:17 AM
After-Hours Stock Movers 05/24: (AERI) (GES) (PSTG) Higher; (CMRE) (OZRK) (NTAP) Lower (more...)
May 24, 2017 6:09 PM
Aerie Pharma (AERI) Roclatan 0.02%/0.005% Phase 3 Trial Achieves Primary Efficacy Endpoint
May 24, 2017 4:12 PM
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results
May 24, 2017 4:01 PM
